1,095 results on '"Holdenrieder Stefan"'
Search Results
52. Inverse association of alanine aminotransferase within normal range with prognosis in patients with coronary artery disease
53. Value of Rotational Thromboelastometry and Impedance Aggregometry for Evaluating Coagulation Disorders in Patients With Cyanotic and Nongenetic Congenital Heart Disease
54. The emerging role of cell-free DNA as a molecular marker for cancer management
55. Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study.
56. Plasma Soluble Glycoprotein VI, Platelet Function, Bleeding, and Ischemic Events in Patients Undergoing Elective Percutaneous Coronary Intervention.
57. Bioactive adrenomedullin (bio-ADM) is associated with endothelial dysfunction in infants and children with complex congenital heart disease undergoing open-heart surgery on cardiopulmonary bypass.
58. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update
59. Incidence of systemic inflammatory response syndrome and patient outcome following transcatheter edge-to-edge mitral valve repair
60. Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies
61. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission
62. A pocket companion to cell-free DNA (cfDNA) preanalytics
63. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan
64. Method Comparison and Clinical Performance of Breast Cancer Tumor Markers on Novel Multiplex Immunoassay and Automatized LOCI Technology Platforms
65. Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC
66. Multi-Omic Candidate Screening for Markers of Severe Clinical Courses of COVID-19
67. Plasma Soluble Glycoprotein VI, Platelet Function, Bleeding, and Ischemic Events in Patients Undergoing Elective Percutaneous Coronary Intervention
68. Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer
69. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150
70. MIC Molecules
71. Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation
72. Auf dem Weg zur multimodalen Nukleinsäurediagnostik im Blutplasma.
73. Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients
74. Longitudinal Evaluation of AFP and CEA External Proficiency Testing Reveals Need for Method Harmonization
75. Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies
76. Academia Meets Industry
77. Liquid Profiling of Circulating Nucleic Acids as a Novel Tool for the Management of Cancer Patients
78. German Society for Clinical Chemistry and Laboratory Medicine – areas of expertise: Division reports from the German Congress of Laboratory Medicine 2022 in Mannheim, 13–14 October 2022
79. Prognostic value of alkaline phosphatase in patients with acute coronary syndromes
80. Soluble ST2 for Risk Stratification and the Prediction of Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation
81. Clinical and laboratory considerations: determining an antibody-based composite correlate of risk for reinfection with SARS-CoV-2 or severe COVID-19.
82. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
83. Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer.
84. A pocket companion to cell-free DNA (cfDNA) preanalytics.
85. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update.
86. Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies.
87. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
88. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan.
89. A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients.
90. Liver cancer Liver cancer Immunogenic Cell Death Markers in Liver Cancer
91. CNAPS in Therapy Monitoring
92. Pre-Analytical Evaluation of Streck Cell-Free DNA Blood Collection Tubes for Liquid Profiling in Oncology
93. zlog-NT-proBNP bei Kindern mit angeborenen Herzfehlern
94. Cell-Free DNA in Plasma and Serum Indicates Disease Severity and Prognosis in Blunt Trauma Patients
95. High-mobility group box 1 protein, receptor for advanced glycation end products and nucleosomes increases after marathon
96. Immature Platelet Fraction Predicts Adverse Events in Patients With Acute Coronary Syndrome: the ISAR-REACT 5 Reticulated Platelet Substudy
97. Myosin binding protein H-like (MYBPHL): a promising biomarker to predict atrial damage
98. RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma
99. De Ritis ratio and long‐term major cardiovascular adverse events in patients undergoing elective percutaneous coronary intervention
100. Measurement of Platelet Aggregation in Ageing Samples and After in-Vitro Activation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.